PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsNicotine
Nicotine
Habitrol, Nicoderm Cq, Nicotine, Nicotrol (nicotine) is a small molecule pharmaceutical. Nicotine was first approved as Nicotrol on 1996-03-22. It is used to treat tobacco use disorder and ulcerative colitis in the USA. It is known to target transient receptor potential cation channel subfamily A member 1, P2Y purinoceptor 11, hydroxycarboxylic acid receptor 1, neuronal acetylcholine receptor subunit alpha-4, hydroxycarboxylic acid receptor 2, transient receptor potential cation channel subfamily M member 2, A-type voltage-gated potassium channel KCND3, neuronal acetylcholine receptor subunit alpha-9, hydroxycarboxylic acid receptor 3, neuronal acetylcholine receptor subunit alpha-10, and neuronal acetylcholine receptor subunit alpha-3.
Download report
Favorite
Searched
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
digestive system diseasesD004066
chemically-induced disordersD064419
mental disordersD001523
Trade Name
FDA
EMA
Habitrol, Nicoderm cq, Nicorette, Nicotine, Nicotine polacrilex, Nicotrol (discontinued: Nicotine polacrilex, Nicotrol, Prostep, Thrive)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Nicotine polacrilex
Tradename
Company
Number
Date
Products
NICORETTEGSKN-018612 OTC1996-02-09
1 products, RLD
NICORETTE (MINT)GSKN-018612 OTC1998-12-23
1 products, RLD
NICORETTEGSKN-018612 OTC2000-09-25
1 products, RLD
NICORETTEGSKN-020066 OTC1996-02-09
1 products, RLD, RS
NICORETTE (MINT)GSKN-020066 OTC1998-12-23
1 products, RLD
NICORETTEGSKN-020066 OTC2000-09-25
1 products, RLD
NICORETTEGSKN-022360 OTC2009-05-18
2 products, RLD, RS
NICORETTEGSKN-021330 OTC2002-10-31
2 products, RLD, RS
Nicotine
Tradename
Company
Number
Date
Products
NICODERM CQSanofiN-020165 OTC1996-08-02
3 products, RLD
HABITROLDr Reddys LaboratoriesN-020076 OTC1999-11-12
3 products, RLD, RS
NICOTROLPfizerN-020385 RX1996-03-22
1 products, RLD, RS
Show 3 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
amazon basic care nicotine polacrilexANDA2025-05-02
aroamas cot nicotine transdermal patches kitC2002632025-06-24
aroamas cot nicotine transdermal patches step 1C2002632025-12-08
aroamas cot nicotine transdermal patches step 2C2002632025-12-09
aroamas cot nicotine transdermal patches step 3C2002632025-12-09
basic care nicotineANDA2026-06-26
berkley and jensen nicotineANDA2026-06-25
berkley and jensen nicotine polacrilexANDA2025-09-20
blipANDA2026-06-11
botasun quit smoking nicotineC2002632026-06-14
Show 122 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
ulcerative colitisEFO_0000729D003093K51
tobacco use disorder—D014029F17
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N07: Other nervous system drugs in atc
— N07B: Drugs used in addictive disorders
— N07BA: Drugs used in nicotine dependence
— N07BA01: Nicotine
HCPCS
Code
Description
S4990
Nicotine patches, legend
S4991
Nicotine patches, non-legend
Clinical
Clinical Trials
2713 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Tobacco use disorderD014029—F17871235067332625
Smoking cessationD016540EFO_0004319—43564073287481
SmokingD012907EFO_0004318—34392238229346
Cigarette smokingD000073865——2125617112174
VapingD000072137——7839115142
Tobacco useD064424—Z72.09573120142
Tobacco smokingD000073869——7521293117
Tobacco use cessationD020340——4127135788
Substance-related disordersD019966EFO_0003890F1373155873
DepressionD003863—F33.946525973
Show 94 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetes mellitusD003920EFO_0000400E08-E13—12—1720
Harm reductionD040261——323—1017
Covid-19D000086382—U07.1—34—714
Post-traumatic stress disordersD013313EFO_0001358F43.1211—1114
AnesthesiaD000758————1—1213
Lung diseasesD008171EFO_0003818J98.4111—912
AsthmaD001249EFO_0000270J45—21—912
Wounds and injuriesD014947—T14.8——2—1012
Traumatic stress disordersD040921——211—710
InfectionsD007239EFO_0000544———1—78
Show 59 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
RecurrenceD012008———2———2
Substance-related disordersD019966EFO_0003890F1311———2
Human influenzaD007251EFO_0007328J11.1—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SchizophreniaD012559EFO_0000692F201————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Psychological well-beingD000092862——————1616
Motor activityD009043EFO_0003940—————1313
Acceptance and commitment therapyD064869——————1111
Heart disease risk factorsD000082742——————1010
SuicideD013405——————1010
HypoxiaD000860—R09.02————1010
BehaviorD001519GO_0007610STY/T053————99
Sedentary behaviorD057185——————99
Health behaviorD015438——————88
ApneaD001049—R06.81————88
Show 493 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameNicotine
INN—
Description
(S)-nicotine is a 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum. It has a role as a phytogenic insecticide, a teratogenic agent, a neurotoxin, an anxiolytic drug, a nicotinic acetylcholine receptor agonist, a biomarker, an immunomodulator, a mitogen, a peripheral nervous system drug, a psychotropic drug, a plant metabolite and a xenobiotic. It is a conjugate base of a (S)-nicotinium(1+). It is an enantiomer of a (R)-nicotine.
Classification
Small molecule
Drug classStimulant; Nootropic; Euphoriant
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CN1CCC[C@H]1c1cccnc1
Identifiers
PDB—
CAS-ID54-11-5
RxCUI—
ChEMBL IDCHEMBL3
ChEBI ID17688
PubChem CID89594
DrugBankDB00184
UNII ID—
Target
Agency Approved
No data
Alternate
KCND3
KCND3
Organism
Homo sapiens
Gene name
KCND3
Gene synonyms
NCBI Gene ID
3752
Protein name
potassium voltage-gated channel subfamily D member 3
Protein synonyms
potassium channel, voltage gated Shal related subfamily D, member 3, potassium ionic channel Kv4.3, potassium voltage-gated channel long, potassium voltage-gated channel, Shal-related subfamily, member 3, sha1-related potassium channel Kv4.3, voltage-gated K+ channel, Voltage-gated potassium channel subunit Kv4.3
Uniprot ID
Q9UK17
Mouse ortholog
Kcnd3 (56543)
potassium voltage-gated channel subfamily D member 3 (Q9Z0V1)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Nicotine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 132,965 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
63,820 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use